Genetic modification of the lung directed toward treatment of human disease

Dolan Sondhi, Katie M. Stiles, Bishnu P. De, Ronald Crystal

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Geneticmodification therapy isapromising therapeutic strategy formanydiseases of thelung intractable to other treatments. Lung gene therapy has been the subject of numerous preclinical animal experiments and human clinical trials, for targets including genetic diseases such as cystic fibrosis and a1-antitrypsin deficiency, complex disorders such as asthma, allergy, and lung cancer, infections such as respiratory syncytial virus (RSV) and Pseudomonas, aswell as pulmonary arterial hypertension, transplant rejection, andlung injury.Avariety of viral and non-viral vectors have been employed to overcome the many physical barriers to gene transfer imposed by lung anatomy and natural defenses. Beyond the treatment of lung diseases, the lung has the potential to be used as a metabolic factory for generating proteins for delivery to the circulation for treatment of systemic diseases. Althoughmuch has been learned through amyriad of experiments about the development of genetic modification of the lung, more work is still needed to improve the delivery vehicles and to overcome challenges such as entry barriers, persistent expression, specific cell targeting, and circumventing host anti-vector responses.

Original languageEnglish
Pages (from-to)3-84
Number of pages82
JournalHuman Gene Therapy
Volume28
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017
Externally publishedYes

Fingerprint

Lung
Therapeutics
Architectural Accessibility
Inborn Genetic Diseases
Respiratory Syncytial Viruses
Graft Rejection
Pseudomonas
Pulmonary Hypertension
Cystic Fibrosis
Genetic Therapy
Lung Diseases
Lung Neoplasms
Anatomy
Hypersensitivity
Asthma
Clinical Trials
Wounds and Injuries
Infection
Genes
Proteins

Keywords

  • Gene therapy
  • Lung
  • Lung disease
  • Non-viral vectors
  • Viral vectors

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Genetic modification of the lung directed toward treatment of human disease. / Sondhi, Dolan; Stiles, Katie M.; De, Bishnu P.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 28, No. 1, 01.01.2017, p. 3-84.

Research output: Contribution to journalReview article

Sondhi, Dolan ; Stiles, Katie M. ; De, Bishnu P. ; Crystal, Ronald. / Genetic modification of the lung directed toward treatment of human disease. In: Human Gene Therapy. 2017 ; Vol. 28, No. 1. pp. 3-84.
@article{08a84f9665eb407ab0162f0d1704b65f,
title = "Genetic modification of the lung directed toward treatment of human disease",
abstract = "Geneticmodification therapy isapromising therapeutic strategy formanydiseases of thelung intractable to other treatments. Lung gene therapy has been the subject of numerous preclinical animal experiments and human clinical trials, for targets including genetic diseases such as cystic fibrosis and a1-antitrypsin deficiency, complex disorders such as asthma, allergy, and lung cancer, infections such as respiratory syncytial virus (RSV) and Pseudomonas, aswell as pulmonary arterial hypertension, transplant rejection, andlung injury.Avariety of viral and non-viral vectors have been employed to overcome the many physical barriers to gene transfer imposed by lung anatomy and natural defenses. Beyond the treatment of lung diseases, the lung has the potential to be used as a metabolic factory for generating proteins for delivery to the circulation for treatment of systemic diseases. Althoughmuch has been learned through amyriad of experiments about the development of genetic modification of the lung, more work is still needed to improve the delivery vehicles and to overcome challenges such as entry barriers, persistent expression, specific cell targeting, and circumventing host anti-vector responses.",
keywords = "Gene therapy, Lung, Lung disease, Non-viral vectors, Viral vectors",
author = "Dolan Sondhi and Stiles, {Katie M.} and De, {Bishnu P.} and Ronald Crystal",
year = "2017",
month = "1",
day = "1",
doi = "10.1089/hum.2016.152",
language = "English",
volume = "28",
pages = "3--84",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Genetic modification of the lung directed toward treatment of human disease

AU - Sondhi, Dolan

AU - Stiles, Katie M.

AU - De, Bishnu P.

AU - Crystal, Ronald

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Geneticmodification therapy isapromising therapeutic strategy formanydiseases of thelung intractable to other treatments. Lung gene therapy has been the subject of numerous preclinical animal experiments and human clinical trials, for targets including genetic diseases such as cystic fibrosis and a1-antitrypsin deficiency, complex disorders such as asthma, allergy, and lung cancer, infections such as respiratory syncytial virus (RSV) and Pseudomonas, aswell as pulmonary arterial hypertension, transplant rejection, andlung injury.Avariety of viral and non-viral vectors have been employed to overcome the many physical barriers to gene transfer imposed by lung anatomy and natural defenses. Beyond the treatment of lung diseases, the lung has the potential to be used as a metabolic factory for generating proteins for delivery to the circulation for treatment of systemic diseases. Althoughmuch has been learned through amyriad of experiments about the development of genetic modification of the lung, more work is still needed to improve the delivery vehicles and to overcome challenges such as entry barriers, persistent expression, specific cell targeting, and circumventing host anti-vector responses.

AB - Geneticmodification therapy isapromising therapeutic strategy formanydiseases of thelung intractable to other treatments. Lung gene therapy has been the subject of numerous preclinical animal experiments and human clinical trials, for targets including genetic diseases such as cystic fibrosis and a1-antitrypsin deficiency, complex disorders such as asthma, allergy, and lung cancer, infections such as respiratory syncytial virus (RSV) and Pseudomonas, aswell as pulmonary arterial hypertension, transplant rejection, andlung injury.Avariety of viral and non-viral vectors have been employed to overcome the many physical barriers to gene transfer imposed by lung anatomy and natural defenses. Beyond the treatment of lung diseases, the lung has the potential to be used as a metabolic factory for generating proteins for delivery to the circulation for treatment of systemic diseases. Althoughmuch has been learned through amyriad of experiments about the development of genetic modification of the lung, more work is still needed to improve the delivery vehicles and to overcome challenges such as entry barriers, persistent expression, specific cell targeting, and circumventing host anti-vector responses.

KW - Gene therapy

KW - Lung

KW - Lung disease

KW - Non-viral vectors

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=85009987962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009987962&partnerID=8YFLogxK

U2 - 10.1089/hum.2016.152

DO - 10.1089/hum.2016.152

M3 - Review article

VL - 28

SP - 3

EP - 84

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -